Industry Report: 10 DTx Companies Convene for 'DTx Business Roundtable 2026'

CureApp, the first company in Japan to commercialize prescription digital therapeutics, hosted the 'DTx Business Roundtable 2026' on May 21, 2026. The event brought together 10 leading companies at the forefront of the industry to establish sustainable business models for Digital Therapeutics (DTx).

During the session, participants discussed the 'three walls' that CureApp has faced—specifically in development/clinical trials, insurance reimbursement, and sales—along with other industry-wide challenges. The companies affirmed a commitment to collective industry growth and are currently planning a large-scale conference to serve as a cornerstone for the sector.

◆Background and Objectives
The purpose of the roundtable was to foster collaboration among previously isolated players, allowing them to share know-how and raise the standard of the entire industry.

◆Participating Companies (in no particular order)
CureApp, Inc., BiPSEE, Inc., CaTe, Inc., DT Axis, Inc., emol, Inc., Meiji Seika Pharma Co., Ltd., MICIN, Inc., Sawai Pharmaceutical Co., Ltd., and two others, totaling 10 companies.

◆Key Discussion Highlights
・The Three Walls: CureApp shared its experiences navigating barriers in clinical trials, insurance coverage, and sales.
・Future Outlook: Participants exchanged views on cross-industry collaboration and the standardization of sales operations in preparation for the upcoming '1st DTx Conference.'